William Blair research analyst Matt Phipps connected with Reuters to discuss the impact of Amgen’s acquisition of biotech company Horizon Therapeutics.
Phipps told the publication that while the deal adds to Amgen’s portfolio of drugs, it is structured with debt instruments, which could impact earnings ratios.